Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)

SHA:600196 Revenue

Shanghai Fosun Pharmaceutical (Group) had revenue of 10.02B CNY in the quarter ending September 30, 2026, with 1.44% growth. This brings the company's total for the last twelve months to 42.73B, up 8.05% year-over-year. In the year 2025, Shanghai Fosun Pharmaceutical (Group) had annual revenue of 41.66B with 1.45% growth. That makes Shanghai Fosun Pharmaceutical (Group) the 2,172nd largest company in the world by revenue and 236th in China.

• Revenue (ttm): 42.73B
• Revenue Growth: +8.05%
• P/S Ratio: 1.30
• Revenue / Employee: 1.05M
• Employees: 40,684
• Market Cap: 55.53B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Manufacturing 29.95B 71.5%
• Health care Service 7.39B 17.6%
• Medical Devices and Medical Diagnosis 4.34B 10.4%
• Others 209.29M 0.5%

By Geography

Chart

• Mainland China 28.68B 68.9%
• Other Countries or Regions 12.98B 31.1%

Fiscal year ended Dec 31, 2025 See the full SHA:600196 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	41.66B	594.42M	1.45%
Dec 31, 2024	41.07B	-332.34M	-0.80%
Dec 31, 2023	41.40B	-2.55B	-5.81%
Dec 31, 2022	43.95B	4.94B	12.66%
Dec 31, 2021	39.01B	8.70B	28.72%

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error